Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.

IR Contact
Torbjørn Furuseth
Torbjørn Furuseth
CFO
+47 932 11 101
Renate Birkeli
Renate Birkeli
Investor Relations
+47 922 61 624